These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24192770)

  • 1. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
    Martin LK; Bekaii-Saab T; Serna D; Monk P; Clinton SK; Grever MR; Kraut EH
    Onkologie; 2013; 36(11):657-60. PubMed ID: 24192770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
    Hoff PM; Wolff RA; Bogaard K; Waldrum S; Abbruzzese JL
    Jpn J Clin Oncol; 2006 Feb; 36(2):100-3. PubMed ID: 16449240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
    Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
    Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
    Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
    Saltz LB; Spriggs D; Schaaf LJ; Schwartz GK; Ilson D; Kemeny N; Kanowitz J; Steger C; Eng M; Albanese P; Semple D; Hanover CK; Elfring GL; Miller LL; Kelsen D
    J Clin Oncol; 1998 Dec; 16(12):3858-65. PubMed ID: 9850031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
    Tew WP; Radovich D; O'Reilly E; Schwartz G; Schrag D; Saltz LB; Kelsen DP; Kepler S; Ilson DH
    Invest New Drugs; 2009 Aug; 27(4):366-73. PubMed ID: 18956138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
    Lockhart AC; Cropp GF; Berlin JD; Donnelly E; Schumaker RD; Schaaf LJ; Hande KR; Fleischer AC; Hannah AL; Rothenberg ML
    Am J Clin Oncol; 2006 Apr; 29(2):109-15. PubMed ID: 16601426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
    Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
    Hilgers W; Faivre S; Chieze S; Alexandre J; Lokiec F; Goldwasser F; Raymond E; Kahatt C; Taamma A; Weems G; MacDonald JR; Misset JL; Cvitkovic E
    Invest New Drugs; 2006 Jul; 24(4):311-9. PubMed ID: 16683074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
    de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
    J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
    Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
    Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
    J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
    Kuenen BC; Rosen L; Smit EF; Parson MR; Levi M; Ruijter R; Huisman H; Kedde MA; Noordhuis P; van der Vijgh WJ; Peters GJ; Cropp GF; Scigalla P; Hoekman K; Pinedo HM; Giaccone G
    J Clin Oncol; 2002 Mar; 20(6):1657-67. PubMed ID: 11896117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
    O'Donnell A; Padhani A; Hayes C; Kakkar AJ; Leach M; Trigo JM; Scurr M; Raynaud F; Phillips S; Aherne W; Hardcastle A; Workman P; Hannah A; Judson I
    Br J Cancer; 2005 Oct; 93(8):876-83. PubMed ID: 16222321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.